USNA Usana Health Sciences Inc
Price (delayed)
$24.24
Market cap
$458.25M
P/E Ratio
11.02
Dividend/share
N/A
EPS
$2.2
Enterprise value
$299.48M
USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25
Highlights
The price to earnings (P/E) is 29% lower than the 5-year quarterly average of 15.6 and 27% lower than the last 4 quarters average of 15.1
The company's equity rose by 7% YoY
The quick ratio has plunged by 59% from the previous quarter and by 53% YoY
The EPS has contracted by 34% YoY and by 23% from the previous quarter
Key stats
What are the main financial stats of USNA
Market
Valuations
Earnings
Shares outstanding
18.9M
Market cap
$458.25M
Enterprise value
$299.48M
Price to earnings (P/E)
11.02
Price to book (P/B)
0.87
Price to sales (P/S)
0.54
EV/EBIT
3.91
EV/EBITDA
3.03
EV/Sales
0.35
Revenue
$854.5M
Gross profit
$693.29M
Operating income
$66.32M
Net income
$42.03M
EBIT
$76.6M
EBITDA
$98.83M
Free cash flow
$50.98M
Per share
Balance sheet
Liquidity
EPS
$2.2
EPS diluted
$2.19
Free cash flow per share
$2.67
Book value per share
$27.92
Revenue per share
$44.73
TBVPS
$23.67
Total assets
$748.19M
Total liabilities
$161.86M
Debt
$23M
Equity
$532.11M
Working capital
$139.56M
Debt to equity
0.04
Current ratio
2
Quick ratio
1.3
Net debt/EBITDA
-1.61
Margins
Efficiency
Dividend
EBITDA margin
11.6%
Gross margin
81.1%
Net margin
4.9%
Operating margin
7.8%
Return on assets
6.3%
Return on equity
8.1%
Return on invested capital
51.7%
Return on capital employed
12.6%
Return on sales
9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
USNA stock price
How has the Usana Health Sciences stock price performed over time
Intraday
1.72%
1 week
0.96%
1 month
-11.24%
1 year
-45.2%
YTD
-32.46%
QTD
-10.12%
Financial performance
How have Usana Health Sciences's revenue and profit performed over time
Revenue
$854.5M
Gross profit
$693.29M
Operating income
$66.32M
Net income
$42.03M
Gross margin
81.1%
Net margin
4.9%
USNA's net income is down by 34% year-on-year and by 23% since the previous quarter
The operating income has declined by 29% year-on-year and by 19% since the previous quarter
USNA's net margin is down by 29% YoY and by 22% from the previous quarter
Usana Health Sciences's operating margin has decreased by 23% YoY and by 19% QoQ
Growth
What is Usana Health Sciences's growth rate over time
Valuation
What is Usana Health Sciences stock price valuation
P/E
11.02
P/B
0.87
P/S
0.54
EV/EBIT
3.91
EV/EBITDA
3.03
EV/Sales
0.35
The EPS has contracted by 34% YoY and by 23% from the previous quarter
The price to earnings (P/E) is 29% lower than the 5-year quarterly average of 15.6 and 27% lower than the last 4 quarters average of 15.1
USNA's P/B is 72% below its 5-year quarterly average of 3.1 and 42% below its last 4 quarters average of 1.5
The company's equity rose by 7% YoY
USNA's price to sales (P/S) is 58% less than its 5-year quarterly average of 1.3 and 40% less than its last 4 quarters average of 0.9
USNA's revenue is down by 7% year-on-year
Efficiency
How efficient is Usana Health Sciences business performance
Usana Health Sciences's ROA has decreased by 38% YoY and by 26% from the previous quarter
The ROE has contracted by 37% YoY and by 24% from the previous quarter
The company's return on invested capital fell by 31% YoY and by 20% QoQ
The ROS has contracted by 20% YoY and by 17% from the previous quarter
Dividends
What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for USNA.
Financial health
How did Usana Health Sciences financials performed over time
The quick ratio has plunged by 59% from the previous quarter and by 53% YoY
The current ratio has decreased by 49% from the previous quarter and by 43% YoY
USNA's debt is 96% less than its equity
The company's equity rose by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.